Cargando…
Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
The tumor genome of a patient with advanced pancreatic cancer was sequenced to identify potential therapeutic targetable mutations after standard of care failed to produce any significant overall response. Matched tumor-normal whole-genome sequencing revealed somatic mutations in BRAF, TP53, CDKN2A,...
Autores principales: | Wrzeszczynski, Kazimierz O., Rahman, Sadia, Frank, Mayu O., Arora, Kanika, Shah, Minita, Geiger, Heather, Felice, Vanessa, Manaa, Dina, Dikoglu, Esra, Khaira, Depinder, Chimpiri, A. Rao, Michelini, Vanessa V., Jobanputra, Vaidehi, Darnell, Robert B., Powers, Scott, Choi, Minsig |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913137/ https://www.ncbi.nlm.nih.gov/pubmed/31519698 http://dx.doi.org/10.1101/mcs.a004424 |
Ejemplares similares
-
Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer
por: Wrzeszczynski, Kazimierz O., et al.
Publicado: (2018) -
Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013) -
Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019) -
Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023) -
Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma
por: McGettigan, Suzanne
Publicado: (2014)